Developer docs
API playgroundTry for free, no card

Search company profiles

Genomics

Full company profile

uuid000bgxc

Namestring
Genomics
Legal namestring
Genomics Ltd
Websiteurl
genomics.com
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersOxford, United Kingdom
HQ citystring
Oxford
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug target discovery, polygenic risk scores, human genetics platform, population health prediction, AI genomics software
Industry4 codes
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI-enabled genomics and drug discovery software
Social media profiles2 records
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Mystra AI SaaS Subscriptions
TypeSubscription Recurring
Description

Self-service SaaS enrollment for teams to access Mystra AI platform, proprietary datasets and analysis tools. Flexible engagement models including partly managed and fully managed services.

genomics.com
2B2B Partnerships with Life Sciences
TypeSubscription Recurring
Description

Revenue from pharmaceutical partnerships for drug target identification, validation, and clinical trial optimization services. Includes collaborations with companies like BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics.

genomics.com
3Healthcare and Population Health Solutions
TypeSubscription Recurring
Description

Risk prediction and stratification tools delivered to healthcare systems, insurers, and employers for population health management, underwriting, and employee wellness programs.

genomics.com
4Individual Health Insights
TypeSubscription Recurring
Description

Direct-to-consumer or employer-proxied access to genomic health assessments for disease risk prediction and personalized action plans.

genomics.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure
Pricing details3 tiers
1Self-service SaaS - Direct platform access
ModelSubscriptionBilling cadenceAnnual
Notes

Enrol teams for direct access to Mystra AI, leveraging the platform's proprietary datasets and analysis tools

genomics.com
2Partly Managed - Combined data analysis
ModelHybridBilling cadenceAnnual
Notes

Bring proprietary internal data to securely combine with Genomics' world-leading datasets for bespoke analysis

genomics.com
3Fully Managed - Collaborative engagement
ModelSubscriptionBilling cadenceAnnual
Notes

Collaborate with Genomics' team of over 60 statistical genetic scientists to supercharge pipelines and accelerate breakthroughs

genomics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 3 records shown
1Mystra
Description

AI-enabled human genetics platform for drug target discovery and validation, powered by the company's genotype-phenotype database.

genomics.com
+2 more records
Core offering1 text field

Genomics is a health-tech company that sells an AI-enabled human genetics platform (Mystra AI) for pharmaceutical drug target discovery and validation, alongside population health risk-prediction solutions for healthcare systems, insurers, employers, and individual consumers. Its core assets are a proprietary genotype-phenotype database built over 10+ years (45,000+ GWAS studies) and a team of 60+ statistical genetic scientists, with revenue primarily generated through SaaS subscriptions and enterprise partnerships.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Drug targets with human genetic support are 2.6 times more likely to succeed in clinical trials
+4 more records
Product overview1 text field

Genomics operates as a multi-product platform company with two core offerings: (1) Mystra AI - an AI-enabled human genetics platform for pharmaceutical drug target discovery and validation, and (2) a suite of population health management solutions spanning Health Insights UK, Health Insights USA, and direct-to-consumer genomic testing for individuals. The company also offers sector-specific solutions for insurance partners, employers, healthcare providers, and life sciences companies. All offerings are powered by the company's proprietary genotype-phenotype database, one of the world's largest with over 45,000 GWAS studies.

Product and service8 records
1Mystra AI
CategoryAI-enabled human genetics platform
Description

Agentic AI platform for drug target discovery and validation, built on the world's largest human genotype-phenotype database (45,000+ GWAS studies). Provides a conversational natural-language interface enabling pharmaceutical and biotech R&D and BD&L scientists to query genetic evidence and accelerate drug pipelines without deep analytical expertise.

2Health Insights UK
CategoryPopulation health risk prediction
Description

Population health management platform for the UK NHS and healthcare providers, providing genomic risk prediction and stratification tools to identify at-risk individuals early and enable precision screening and prevention.

3Health Insights USA
CategoryPopulation health risk prediction
Description

Population health management platform for the US market, delivering precision health through genomic risk prediction and stratification for individuals and populations.

4For Healthcare Solution
CategoryClinical genomics solutions
Description

Clinical risk prediction and stratification tools for healthcare providers, hospitals, and medical practices, enabling precision health delivery through genomic risk prediction and population health management.

5For Life Sciences Solution
CategoryDrug discovery and biomarker solutions
Description

Drug discovery and biomarker identification solutions for pharmaceutical and biotech companies, including target discovery, clinical trial design optimization, and post-market studies powered by Genomics' genetic and multi-omics data.

6For Partners (Insurance) Solution
CategoryInsurance and underwriting solutions
Description

Genetic risk scoring and predictive genomics solution for insurance and long-term care partners, used to minimise underwriting risk and maximise lifetime customer value through polygenic risk scores from a single at-home test.

7For Employers Solution
CategoryEmployer wellness benefits
Description

Workplace wellness platform providing employees with personalised genomic health insights and action plans to identify health risks early, improve wellbeing, and reduce healthcare costs.

8Genomic Health Insights for Individuals
CategoryConsumer genomic testing
Description

Direct-to-consumer genetic testing service that assesses an individual's predisposition to cancer, heart disease, diabetes, and 20+ conditions using a simple at-home saliva test, returning personalised risk reports and action plans.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership12 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Early adopter of Mystra AI platform. BridgeBio Pharma uses the agentic AI platform for day-to-day workflow acceleration in mining genomics data for drug target discovery and validation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-06-02
Description

Early adopter of Mystra AI platform. Relation Therapeutics leverages Genomics' genotype-phenotype database for proprietary drug discovery efforts, exploring and evaluating biological insights at pace.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-29
Description

Strategic partnership to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk. The collaboration aims to identify and validate ERAP1 and ERAP2 as therapeutic targets for conditions including axial spondyloarthritis, inflammatory bowel disease, and psoriasis.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-12
Description

Partnership to advance rare disease drug discovery and development. Research presented at ACMG Clinical Genetics Meeting focused on three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2) to support earlier genetic diagnosis and expand treatment access.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Featured partner in Endpoints News coverage of Mystra launch. Mishal Patel, Head of AI at Novo Nordisk, quoted about the platform's capabilities for drug developers.

6NHS
Strategic tierCoreTypeStrategic or Co-development Partner
Description

NHS partnership for HEART trial - the 1st in the world to demonstrate clinical utility of integrated genomic risk tools. Results show 24% of participants had clinically significant changes in CVD risk when genetics was integrated with QRISK.

genomics.com
Strategic tierNotableTypeStrategic or Co-development Partner
Description

Healthcare solutions partner listed on For Healthcare page alongside NHS, Vertex Pharmaceuticals, and GSK.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among collaborators on healthcare solutions page.

Strategic tierNotableTypeStrategic or Co-development Partner
Description

Pharmaceutical partner listed among collaborators on healthcare solutions page.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Government partner for BIO 2026 reception in San Diego. Health Minister Preet Kaur Gill delivered welcome address at the VIP event celebrating UK life sciences.

Strategic tierStrategicTypeGTM or Marketing Partner
Description

Industry association partner. CEO Chris Molloy provided endorsement of Mystra AI launch, noting the UK's ability to harness genomic data for patient and economic benefit.

Strategic tierNotableTypeTechnology or Integration
Description

Technology partner. Rowland Illing, Chief Medical Officer at AWS, provided testimonial calling Genomics' platform transformational for disease and target identification.

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery platform combining high-throughput biology with machine learning. Highly comparable to Genomics' Mystra AI as both sell AI-enabled target discovery and validation tools to pharma R&D organizations.

TypeDirect peer
Description

Machine learning-driven drug discovery company combining human genetics, cellular models, and AI to identify targets. Direct competitor in the AI + genetics drug discovery category Genomics addresses.

TypeDirect peer
Description

AI biotech using federated learning on multimodal patient data (genomics, imaging, clinical) for drug discovery and precision medicine; comparable in data-driven AI for pharma R&D and population health.

TypeDirect peer
Description

AI drug discovery company using knowledge graphs and biomedical data to identify novel targets and indications. Comparable in applying AI to biomedical data to accelerate pharma R&D.

TypeDirect peer
Description

AI-driven precision medicine company using patient-derived data and AI for drug discovery and development. Overlaps with Genomics in serving pharma R&D with AI-enabled target identification and clinical trial design.

6Tempus AI
TypeBroad incumbent
Description

Large-scale precision medicine platform combining genomic and clinical data with AI for therapy selection and drug discovery. A broader incumbent with overlapping capabilities in genomics data, AI, and pharma services.

TypeBroad incumbent
Description

Consumer genetics company with one of the largest genotype-phenotype databases and a therapeutics arm. Comparable in DTC genetic health insights and pharma data partnerships; differs in being consumer-first and lacking an AI-target-discovery platform.

TypeDirect peer
Description

Population genomics and digital health company offering genetic testing to employers, health systems, and payers, plus pharma services. Directly comparable in serving employers, insurers, and providers with PRS and genetic risk products.

TypeBroad incumbent
Description

Industry-leading human genetics initiative linked to a major biopharma, leveraging large-scale sequencing for drug discovery. Comparable in genetics-first drug discovery but operates as a captive resource for Regeneron.

TypeBroad incumbent
Description

Computational chemistry and materials platform with AI/ML-driven drug discovery software sold to pharma. Comparable in selling AI-enabled discovery tools to pharma, though focused on computational chemistry vs. human genetics.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability7 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Genomics

AI-enabled genomics and drug discovery softwaregenomics.com

Genomics firmographics

Firmographics
Name
Genomics
Legal name
Genomics Ltd
Website
https://genomics.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Genomics industry classification

Industry
Product category
AI-enabled genomics and drug discovery software
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
SECONDARYHLAAALAD
Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics)
SECONDARYHLAAANAL
Population Genomics & Preventive Precision Health Programs
SECONDARYHLAGAEAD
Genomics & Molecular Diagnostics (Trial Support)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)

Keywords

  • Drug target discovery
  • Polygenic risk scores
  • Human genetics platform
  • Population health prediction
  • AI genomics software

Where Genomics is headquartered

Location

Headquarters

HQ city
Oxford
HQ country
United Kingdom
HQ region
Europe

Offices3 records

Markets served

Genomics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Mystra AI SaaS Subscriptions: Self-service SaaS enrollment for teams to access Mystra AI platform, proprietary datasets and analysis tools. Flexible engagement models including partly managed and fully managed services.
  2. B2B Partnerships with Life Sciences: Revenue from pharmaceutical partnerships for drug target identification, validation, and clinical trial optimization services. Includes collaborations with companies like BridgeBio Pharma, Relation Therapeutics, and Greywolf Therapeutics.
  3. Healthcare and Population Health Solutions: Risk prediction and stratification tools delivered to healthcare systems, insurers, and employers for population health management, underwriting, and employee wellness programs.
  4. Individual Health Insights: Direct-to-consumer or employer-proxied access to genomic health assessments for disease risk prediction and personalized action plans.

Pricing tiers

ModelBillingPrice
SubscriptionAnnualSelf-service SaaS - Direct platform access
HybridAnnualPartly Managed - Combined data analysis
SubscriptionAnnualFully Managed - Collaborative engagement

Go-to-market motion2 records

Distribution channels5 records

Marketing channels5 records

Genomics product offering

Product offering

Core offering

Genomics is a health-tech company that sells an AI-enabled human genetics platform (Mystra AI) for pharmaceutical drug target discovery and validation, alongside population health risk-prediction solutions for healthcare systems, insurers, employers, and individual consumers. Its core assets are a proprietary genotype-phenotype database built over 10+ years (45,000+ GWAS studies) and a team of 60+ statistical genetic scientists, with revenue primarily generated through SaaS subscriptions and enterprise partnerships.

Product overview

Genomics operates as a multi-product platform company with two core offerings: (1) Mystra AI - an AI-enabled human genetics platform for pharmaceutical drug target discovery and validation, and (2) a suite of population health management solutions spanning Health Insights UK, Health Insights USA, and direct-to-consumer genomic testing for individuals. The company also offers sector-specific solutions for insurance partners, employers, healthcare providers, and life sciences companies. All offerings are powered by the company's proprietary genotype-phenotype database, one of the world's largest with over 45,000 GWAS studies.

Differentiator

Problem solved

Functional benefit

Brands

  • Mystra: AI-enabled human genetics platform for drug target discovery and validation, powered by the company's genotype-phenotype database.
  • Health Insights UK
  • Health Insights USA

Products and services

  • Mystra AI Agentic AI platform for drug target discovery and validation, built on the world's largest human genotype-phenotype database (45,000+ GWAS studies). Provides a conversational natural-language interface enabling pharmaceutical and biotech R&D and BD&L scientists to query genetic evidence and accelerate drug pipelines without deep analytical expertise.
  • Health Insights UK Population health management platform for the UK NHS and healthcare providers, providing genomic risk prediction and stratification tools to identify at-risk individuals early and enable precision screening and prevention.
  • Health Insights USA Population health management platform for the US market, delivering precision health through genomic risk prediction and stratification for individuals and populations.
  • For Healthcare Solution Clinical risk prediction and stratification tools for healthcare providers, hospitals, and medical practices, enabling precision health delivery through genomic risk prediction and population health management.
  • For Life Sciences Solution Drug discovery and biomarker identification solutions for pharmaceutical and biotech companies, including target discovery, clinical trial design optimization, and post-market studies powered by Genomics' genetic and multi-omics data.
  • For Partners (Insurance) Solution Genetic risk scoring and predictive genomics solution for insurance and long-term care partners, used to minimise underwriting risk and maximise lifetime customer value through polygenic risk scores from a single at-home test.
  • For Employers Solution Workplace wellness platform providing employees with personalised genomic health insights and action plans to identify health risks early, improve wellbeing, and reduce healthcare costs.
  • Genomic Health Insights for Individuals Direct-to-consumer genetic testing service that assesses an individual's predisposition to cancer, heart disease, diabetes, and 20+ conditions using a simple at-home saliva test, returning personalised risk reports and action plans.

Quantifiable outcome

  • Drug targets with human genetic support are 2.6 times more likely to succeed in clinical trials
  • +4 more outcomes

Companies that use Genomics

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Genomics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability7 records

Feature4 records

Genomics partnerships and signals

Strategic signal

Partnerships

Twelve partnerships are on record, tiered core, notable and strategic.

  • BridgeBio PharmacoreStrategic or Co-development Partner · 2 June 2026Early adopter of Mystra AI platform. BridgeBio Pharma uses the agentic AI platform for day-to-day workflow acceleration in mining genomics data for drug target discovery and validation.
  • Relation TherapeuticscoreStrategic or Co-development Partner · 2 June 2026Early adopter of Mystra AI platform. Relation Therapeutics leverages Genomics' genotype-phenotype database for proprietary drug discovery efforts, exploring and evaluating biological insights at pace.
  • Greywolf TherapeuticscoreStrategic or Co-development Partner · 29 April 2026Strategic partnership to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk. The collaboration aims to identify and validate ERAP1 and ERAP2 as therapeutic targets for conditions including axial spondyloarthritis, inflammatory bowel disease, and psoriasis.
  • BioMarin PharmaceuticalcoreStrategic or Co-development Partner · 12 March 2026Partnership to advance rare disease drug discovery and development. Research presented at ACMG Clinical Genetics Meeting focused on three ultra-rare lysosomal storage disorders (MPS IVA, MPS VI, and CLN2) to support earlier genetic diagnosis and expand treatment access.
  • Novo NordisknotableStrategic or Co-development PartnerFeatured partner in Endpoints News coverage of Mystra launch. Mishal Patel, Head of AI at Novo Nordisk, quoted about the platform's capabilities for drug developers.
  • NHScoreStrategic or Co-development PartnerNHS partnership for HEART trial - the 1st in the world to demonstrate clinical utility of integrated genomic risk tools. Results show 24% of participants had clinically significant changes in CVD risk when genetics was integrated with QRISK.
  • IQVIAnotableStrategic or Co-development PartnerHealthcare solutions partner listed on For Healthcare page alongside NHS, Vertex Pharmaceuticals, and GSK.
  • Vertex PharmaceuticalsnotableStrategic or Co-development PartnerPharmaceutical partner listed among collaborators on healthcare solutions page.
  • GSKnotableStrategic or Co-development PartnerPharmaceutical partner listed among collaborators on healthcare solutions page.
  • UK Department for Business and TradestrategicGTM or Marketing PartnerGovernment partner for BIO 2026 reception in San Diego. Health Minister Preet Kaur Gill delivered welcome address at the VIP event celebrating UK life sciences.
  • BioIndustry Association (BIA)strategicGTM or Marketing PartnerIndustry association partner. CEO Chris Molloy provided endorsement of Mystra AI launch, noting the UK's ability to harness genomic data for patient and economic benefit.
  • Amazon Web Services (AWS)notableTechnology or IntegrationTechnology partner. Rowland Illing, Chief Medical Officer at AWS, provided testimonial calling Genomics' platform transformational for disease and target identification.

Scale indicators8 records

Recent moves8 records

Expansion highlights6 records

Genomics competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery platform combining high-throughput biology with machine learning. Highly comparable to Genomics' Mystra AI as both sell AI-enabled target discovery and validation tools to pharma R&D organizations.
  • Insitro: Machine learning-driven drug discovery company combining human genetics, cellular models, and AI to identify targets. Direct competitor in the AI + genetics drug discovery category Genomics addresses.
  • Owkin: AI biotech using federated learning on multimodal patient data (genomics, imaging, clinical) for drug discovery and precision medicine; comparable in data-driven AI for pharma R&D and population health.
  • BenevolentAI: AI drug discovery company using knowledge graphs and biomedical data to identify novel targets and indications. Comparable in applying AI to biomedical data to accelerate pharma R&D.
  • Exscientia: AI-driven precision medicine company using patient-derived data and AI for drug discovery and development. Overlaps with Genomics in serving pharma R&D with AI-enabled target identification and clinical trial design.
  • Color Health: Population genomics and digital health company offering genetic testing to employers, health systems, and payers, plus pharma services. Directly comparable in serving employers, insurers, and providers with PRS and genetic risk products.

Broad incumbents

  • Tempus AI: Large-scale precision medicine platform combining genomic and clinical data with AI for therapy selection and drug discovery. A broader incumbent with overlapping capabilities in genomics data, AI, and pharma services.
  • 23andMe: Consumer genetics company with one of the largest genotype-phenotype databases and a therapeutics arm. Comparable in DTC genetic health insights and pharma data partnerships; differs in being consumer-first and lacking an AI-target-discovery platform.
  • Regeneron Genetics Center: Industry-leading human genetics initiative linked to a major biopharma, leveraging large-scale sequencing for drug discovery. Comparable in genetics-first drug discovery but operates as a captive resource for Regeneron.
  • Schrodinger: Computational chemistry and materials platform with AI/ML-driven drug discovery software sold to pharma. Comparable in selling AI-enabled discovery tools to pharma, though focused on computational chemistry vs. human genetics.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Genomics social profiles

Digital presence

Genomics compliance and trust

Trust signal

Compliance1 record

Genomics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Genomics leadership team

Management profile

Number of profiles

Profiles5 records

Genomics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Genomics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genomics

What does Genomics do?

Genomics is a health-tech company that sells an AI-enabled human genetics platform (Mystra AI) for pharmaceutical drug target discovery and validation, alongside population health risk-prediction solutions for healthcare systems, insurers, employers, and individual consumers. Its core assets are a proprietary genotype-phenotype database built over 10+ years (45,000+ GWAS studies) and a team of 60+ statistical genetic scientists, with revenue primarily generated through SaaS subscriptions and enterprise partnerships.

Is Genomics a public or private company?

Genomics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Genomics founded?

Genomics was founded in 2014. It employs 51 to 100 people.

Where is Genomics based?

Genomics is headquartered in Oxford, United Kingdom, in the Europe region.

How does Genomics make money?

Four revenue lines are on record. Mystra AI SaaS Subscriptions are the primary driver. The others are B2B Partnerships with Life Sciences, healthcare and Population Health Solutions and individual Health Insights.

Who are Genomics's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insitro, Owkin, BenevolentAI, Exscientia and Color Health. Broad incumbents are Tempus AI, 23andMe, Regeneron Genetics Center and Schrodinger.

Does Genomics have an API?

No public API is recorded for Genomics.

What industry is Genomics in?

Genomics's product category is AI-enabled genomics and drug discovery software. Its primary akta.pro industry code is HLAAANAA, Genomic Profiling & Sequencing-Based Precision Medicine, with a secondary code of HLAAALAD, Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AktienGenomics Ltd. Announces Extension of Strategic Drug Discovery Collaboration with Vertex PharmaceuticalsGenomics Ltd. announced a four-year extension of its drug target discovery and validation collaboration with Vertex Pharmaceuticals, building on an eight-year partnership that began in 2018. The collaboration focuses on using human genetics to identify novel drug targets and biomarkers for precision medicines.PoliticsukTechBio Company, Genomics Launches Mystra AI as UK Seeks ...Genomics Ltd has launched Mystra AI, an agentic artificial intelligence platform designed to help scientists identify and validate drug targets using large-scale human genetics data. The platform, built on what the company claims is the world's largest human genotype and phenotype database with over 45,000 genome-wide association studies, has already been adopted by pharmaceutical companies BridgeBio Pharma and Relation Therapeutics. The launch aligns with UK government ambitions to leverage national strengths in genomics and AI to accelerate drug development, reduce the high failure rate in clinical trials, and support economic growth in the life sciences sector.PoliticsukHow Genomics Can Help Move Healthcare from Sickness to Pr...Dr Rosie Godeseth, Medical Director at Genomics Ltd, argued at the UKAI and Curia Healthcare and Life Sciences Parliamentary Showcase that genomics and polygenic risk scores could help the NHS shift from treating sickness to prevention, but only if funding, evaluation frameworks, and healthcare infrastructure are redesigned to support predictive healthcare. Modelling based on UK Biobank data suggests that PRS could identify 1.9 million additional high-risk cardiovascular disease individuals, preventing approximately 45,300 cardiovascular events over ten years and saving the NHS over £235 million. Dr Godeseth identified three barriers to scaling preventive genomics: financial models that pit prevention against treatment budgets, evaluation frameworks designed for diagnostics rather than probability-based prediction, and infrastructure built for episodic care rather than lifelong genomic use.BioWorldGenomics and Greywolf partner in autoimmune diseasesGenomics Ltd. and Grey Wolf Therapeutics Ltd. have established a strategic relationship to develop first-in-class treatments for autoimmune diseases. The collaboration aims to create new therapies in this area.AijournGreywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune DiseasesGenomics and Greywolf Therapeutics announced a strategic partnership under which Genomics will analyze large-scale genetic datasets to link ERAP enzyme variants with multiple autoimmune diseases, with the resulting insights intended to guide Greywolf's autoimmune pipeline development. The collaboration leverages Genomics' genotype-phenotype data resource to identify and validate ERAP1 and ERAP2 as therapeutic targets for conditions including axial spondyloarthritis, inflammatory bowel disease, and psoriasis. Greywolf's autoimmune treatment candidate GRWD0715 is currently progressing through a Phase 1/2 trial, with plans to expand into additional autoimmune indications.PR NewswireGreywolf Therapeutics and Genomics Launch Strategic Relationship to Develop First‑in‑Class Treatments for Autoimmune DiseasesGenomics announced a strategic partnership with clinical-stage biotech Greywolf Therapeutics to analyze large-scale genetic datasets evaluating how ERAP (Endoplasmic Reticulum Aminopeptidase) enzyme variants influence autoimmune disease risk across multiple conditions. The insights generated will guide Greywolf's selection of indication opportunities and strengthen its autoimmune disease pipeline, which includes a treatment currently in Phase 1/2 trials for axial spondyloarthritis. The collaboration leverages Genomics' proprietary genotype-phenotype data resource to identify and validate ERAP variants as therapeutic targets for conditions affecting approximately 1 in 10 people worldwide.PoliticsukGenomics at Scale: Bridging UK Innovation, Healthcare, an...Genomics Ltd, a company founded by University of Oxford scientists in 2014, opened its flagship office in London's Knowledge Quarter in February 2026, inaugurated by the Minister for Health Innovation and Safety, marking a milestone in the company's growth trajectory. The company, which employs around 130 people across UK and US offices, has developed an MHRA-registered polygenic risk score test now available in the UK and US, following successful results from a 2022 NHS pilot where over 98.5 per cent of patients found cardiovascular disease risk information useful. CEO Peter Donnelly projects that half of all healthcare interactions will be underpinned by genomics by 2035, with the company currently working on novel drug targets for pharmaceutical partners.PR NewswireAmerican College of Medical Genetics and Genomics (ACMG) Clinical Genetics Meeting: Genomics presents new research highlighting underdiagnosis of rare genetic disordersGenomics presented new research at the ACMG Clinical Genetics Meeting in Baltimore on March 12, 2026, providing insights into the genetic epidemiology of three ultra-rare lysosomal storage disorders—MPS IVA, MPS VI, and CLN2 disease—using whole-genome and whole-exome sequencing data from multiple global biobanks. The research, conducted in partnership with BioMarin Pharmaceutical Inc., identifies disease hotspots where underdiagnosis is particularly acute and aims to support earlier, more accurate genetic diagnosis to expand patient access to life-saving treatments.PR NewswireAmerican College of Medical Genetics and Genomics (ACMG) Clinical Genetics Meeting: Genomics presents new research highlighting underdiagnosis of rare genetic disordersGenomics presented new research findings at the ACMG Clinical Genetics Meeting in Baltimore on March 12, 2026, providing insights into the genetic epidemiology of three ultra-rare lysosomal storage disorders: mucopolysaccharidosis IVA and VI and neuronal ceroid lipofuscinosis type 2 disease. The research, conducted using data from multiple global biobanks, characterizes the prevalence and geographic distribution of disease-causing mutations to identify underdiagnosis hotspots. The company, partnered with BioMarin Pharmaceutical Inc., aims to support earlier and more accurate genetic diagnosis and expand patient access to life-saving treatment options.